Anti-cholinesterase and Neuroprotective Activities of Sweet and Bitter Apricot Kernels (Prunus armeniaca L.)

Yasaman Vahedi-Mazdabadi a, Elahe Karimpour-Razkenari b, Tahmineh Akbarzadeh b, c, Hania Lotfian d, Mohammad Toushih e, Neda Roshanravan e, Mina Saeedi f, b and Alireza Ostadrahimi* a

aNutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. bPersian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran. cDepartment of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. dElectrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. eCardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. fMedicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Apricot (Prunus armeniaca L.) is a fruit cultivated in various parts of the world. Both sweet and bitter kernels of apricot have been used for the treatment of different diseases such as loss of memory in Iranian traditional medicine (ITM). In the present study, the inhibitory activity of sweet and bitter extracts of apricot kernels towards cholinesterase (ChE) enzymes, both acetyl and butyrylcholinesterase was examined through Ellman’s method. In addition, neuroprotectivity of aqueous extracts and amygdalin were investigated against H2O2-induced cell death in PC12 neurons. Among them, the best acetylcholinesterase (AChE) inhibitory activity (IC50 = 134.93 ± 2.88 µg/mL) and neuroprotectivity (P-value < 0.0001) were obtained by the aqueous extract of bitter type. It was found that all extracts showed no butyrylcholinesterase (BChE) inhibitory activity.

Keywords: Alzheimer’s disease; Amygdalin; Cholinesterase inhibitors; Neuroprotectivity; P. armeniaca.

Introduction

Alzheimer’s disease (AD) is an age-related progressive neurodegenerative disorder characterized by the deterioration of memory leading to remarkable multilateral cognitive disorders with significant impact on the quality of life (1). It is also known as the most common cause of dementia in old age and according to statistics, the number of patients with dementia was 47 million in 2015 and it will reach 131.5 million by 2050 (2, 3). The reduction of the level of acetylcholine (ACh) in the cerebrospinal fluid, amyloid beta (βA) aggregation, irregular phosphorylation of tau proteins and subsequent formation of neurofibrils tangles in the hippocampal neurons, and oxidative stress have been involved in the pathogenesis of AD (4-7).

Cholinesterase enzymes (ChEs) including acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) belonging to the alpha/beta-hydrolase fold family have different tissue distribution (8). AChE is known to be found in neurons, whereas BChE mostly exists in plaques and tangles in glial...
cells (7). At present, the most promising therapeutic strategy is the inhibition of ChEs to prevent ACh neurotransmitter breakdown in neurons and synaptic clefts leading to the increased level of ACh in the basal forebrain (4). In addition, recent study reported by Mueller et al. revealed diminished mortality in patients with AD using AChE inhibitors (9). Furthermore, recent studies confirmed the efficacy of selective BChE inhibitors to promote the level of ACh and improve cognitive function (10). However, non-cholinergic role of ChEs by augmenting the formation of βA plaques has absorbed lots of attention (10-12). Hence, inhibition of ChEs not only improves the cholinergic function but can also be considered as an efficient strategy for preventing βA formation. Also, ChEs inhibitors have been recently considered for the cognitive improvements of dementia resulting from other neurological conditions such as Lewy body disease, Huntington’s disease, multiple sclerosis (MS), subcortical vascular dementia, and Parkinson’s disease (13, 14).

There is no definite treatment for AD and current four FDA-approved drugs including donepezil, rivastigmine, galantamine, memantine only ameliorate symptoms and the first three are AChE inhibitors (AChEIs). However, lack of significant efficacy and different side effects such as gastrointestinal disturbances, insomnia, fatigue or depression led to the conduction of a wide range of research to develop efficient anti-AD agents based on the multifactorial nature of disease (15). In this regard, various medicinal plants have been investigated for their effectiveness in treating AD and memory deficits. It is predicted that herbal agents regulate disease progression apart from symptomatic treatment (16-19).

Prunus armeniaca L. known as apricot is a delicious stone fruit belonging to family Rosaceae, widely cultivated in the temperate regions such as Iran, Turkey, Pakistan, Iraq, Afghanistan, Syria, Russia, USA, Mediterranean countries, and central Asia. Among them, Iran and Turkey are the main producers in the world (20). In Iran, the fruit is grown throughout the country especially north-west where the climate is suitable for cultivating a highly desirable product. Apricot kernels contain various micronutrients and macronutrients such as fatty acids, sterol derivatives, polyphenols, carotenoids, volatile compounds, and cyanogenic glycosides (CNGs) (21). They are divided into two types of sweet and bitter kernels, depending on the amount of CNGs, mainly amygdalin (D-mandelonitrile-β-D-gentiobioside) which cause a bitter taste (22). They also have shown various pharmacological properties such as anticancer, antimicrobial, cardioprotective, hepatoprotective, antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and neurotrophic activities (21, 23-25). Moreover, apricot kernels were recommended for the treatment of dementia and promotion of the memory in ITM (26).

In this study, according to our previous study on herbal anti-ChE agents and focusing on the efficient biological activity of apricot kernels which were supported by both classic medicine and ITM, anti-ChE and neuroprotective activities of different sweet and bitter apricot kernels’ extracts from north-west of Iran were investigated (27, 28).

**Experimental**

**Plant materials**

The fresh fruits (Prunus armeniaca L.) were collected from Ivand, a village in East Azerbaijan with coordinates (38°20′57″N, 46°07′01″E, at 1632.7m altitude above sea level) on 6 July 2016. They were fetched to the laboratory and the stones were removed. Then, they were identified by Prof. G.R. Amin and the voucher specimens PMP-750 and PMP-768 were deposited in the Herbarium of Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran for sweet and bitter types, respectively.

**Extraction**

The sweet and bitter apricot kernels were shade-dried and then milled using a mortar and pestle, given codes S and B, respectively. Petroleum ether extracts SO and BO: to extract fatty oils, 600 g of S and 130 g of B were separately macerated three times, each time with 3100 mL and 1100 mL petroleum ether, respectively for 72 h at room temperature. The solvent was concentrated under vacuum and
the resulting oils (SO and BO) were stored at 20 °C. Also, the resulting residue in this step was dried at room temperature to give 342 g and 70 g solids S1 and B1, respectively which were used for further extractions including hydroalcoholic, ethanolic, and aqueous extractions.

Hydroalcoholic extracts HS1 and HB1: 300 g of S1 and 50 g of B1 were separately extracted three times with methanol-water (70:30 (v/v) with total volume (3700 mL) and (970 mL) respectively, by maceration for 72 h at room temperature. The extracts were filtered and centrifuged at 4000 rpm for 6 min (Heraeus Megafuge 1.0, England), concentrated using a rotary evaporator under vacuum (Heidolph, Heizbad Hei-VAP, Germany) at 20 °C, and finally freeze-dried (LTE science LTD, England) at 60 °C/10 μmHg for 24 h to obtain desired extracts HS1 and HB1 in 16.30% and 22.74%, respectively which were stored at 20 °C.

Aqueous extracts AS1 and AB1: 10 g of S1 and 10 g of B1 were separately boiled with 150 mL distilled water in a beaker for 10 minutes. Then, they were cooled and filtered. Each solid residue was re-extracted by 50 mL distilled water. They were filtered, centrifuged at 4000 rpm for 6 min, concentrated using a rotary evaporator under vacuum, freeze-dried, and stored at 20 °C to afford desired extracts of AS1 and AB1 in 27.5% and 24.2%, respectively.

Ethanolic extracts ES1 and EB1: 10 g of S1 and 10 g of B1 were separately extracted three times with 245 mL ethanol (96%) by maceration for 72 h at room temperature. Next, the collected solvents were filtered, centrifuged at 4000 rpm for 6 minutes, concentrated using a rotary evaporator under vacuum, freeze-dried, and stored at 20 °C to afford ethanolic extracts of ES1 and EB1 in 7.3% and 6.9%, respectively.

In-vitro AChE and BChE inhibition assays
Anti-AChE and anti-BChE activity of all extracts as well as amygdalin were investigated using modified Ellman’s method (29).

Electric eel (Torpedo Californica) AChE (E.C. 3.1.1.7, type VI-S, lyophilized powder), BChE (E.C.3.1.1.8, from equine serum), acetylthiocholine iodide, butyrylthiocholine iodide, 5, 5'-dithiobis (2-nitrobenzoic acid) (DTNB), amygdalin and rivastigmine were purchased from Sigma (Steinheim, Germany).

10 mg of aqueous extracts of P. armeniaca was dissolved in 1 mL distilled water and the other extracts were dissolved in a mixture of 50% DMSO and 50% methanol to obtain dilution of stock 10 mg/mL and afterwards four different concentrations of each extract were examined to get enzyme inhibition for AChE/BChE. In the case of amygdalin, the stock solution was prepared by dissolving 1 mg of that compound in 1 mL distilled water. In a 96 well plate, 50 μL phosphate buffer (0.1 M, pH 8.0), 25 μL of the sample solution, DMSO/MeOH or distilled water and 25 μL of enzyme [0.22 U/mL of AChE or BChE] was added. The plate was pre-incubated for 15 min at room temperature. Then, 125 μL of DTNB (3 mM in buffer), as well as 25 μL of substrate (3 mM in water) (acetylthiocholine iodide or butyrylthiocholine iodide) was added to each well. Finally, the change of absorbance was recorded at 405 nm after 20 min using a microplate reader (BioTek ELx808, USA).

Rivastigmine was applied as the positive control, while a mixture including buffer, DMSO, DTNB, and substrate was tested under the same conditions without enzyme as the negative control.

Neuroprotection study assays
Rat pheochromocytoma PC12 cell line was purchased from the Pasteur Institute (Tehran, IRAN) and culture media and supplements were purchased from Gibco (Paisley, UK). The cells were cultivated in DMEM supplemented with 10% fetal calf serum plus antibiotics (100 units/mL penicillin, 100 μg/mL streptomycin). To induce neuronal differentiation, PC12 cells were re-suspended using trypsin/EDTA (0.25%) and seeded in 96 well culture plate (4000cells/well) and cultured for 1 week in differentiation medium (DMEM + 2% fetal calf serum + NGF (100 ng/mL) + penicillin and streptomycin). To evaluate the effect of AS1 and AB1 as well as amygdalin on the survival rate of neurons, the culture medium was changed to NGF free medium and different concentrations of the above-
mentioned extracts and amygdalin (1, 10, 100 μg/mL) were applied on cells. Quercetin (3 μg/mL) was applied as a positive control. The extracts and amygdalin were diluted in DMEM and added to each well in the volume of 10 μL. Then, after 3 h, induction of ROS mediated apoptosis was initiated by adding the H₂O₂ (400 μM) to their medium. After 12 h, MTT assay was performed (30). MTT solution (5 mg/mL) was added to each well in a volume of 10 μL, and 3.5 h later, 100 μL of the solubilisation solution (10% SDS in 0.01 M HCl (w/v) was added into each well. The plates were allowed to stand overnight in the incubator in a humidified atmosphere. Absorbance was measured at 570 nm with a reference wavelength of 630 nm using a plate reading spectrophotometer (BioTek ELx808, USA). Each experiment was performed in three replicates.

**Determination of total phenols content**

The total phenolic content of the aqueous extracts possessing anti-ChE activity was assessed using Folin-Ciocalteu assay (31). Folin-Ciocalteu (Steinheim, Germany) and gallic acid (GAE) (Darmstadt, Germany) were purchased from Sigma. The total phenolic content was expressed in gallic acid equivalents as mg per g extract. The calibration equation was (y = 0.0068x−0.0221) (R² = 0.9911) where y is the absorbance at 765 nm using an UV-Vis Spectrophotometer (Mecasys 2120uv, Korea) and x is the concentration of gallic acid mg/g extract.

**Determination of total flavonoids content**

Total flavonoid content in the aqueous extracts was determined by aluminum chloride colorimetric assay (32). Aluminum chloride and catechin (CE) were purchased from Merk (Darmstadt, Germany) and Sigma (Darmstadt, Germany), respectively. Total flavonoid content of aqueous extracts was expressed as mg catechin equivalents per g extract. The calibration equation was (y = 0.002x + 0.0227) (R² = 0.9975) where y is the absorbance at 510 nm and x is the concentration of catechin mg/g extract.

**Statistical analysis**

All experiments were accomplished in triplicates. The IC₅₀ values were estimated graphically from log inhibitor the extract concentration versus percent of inhibition by using Microsoft Excel 2010 program. One-way ANOVA was used to assess significant differences among the treatment groups followed by Tukey's multiple comparisons test that was carried out to determine the level of significance by GraphPad Prism 6 software (San Diego, CA, USA). It means statistically significant when P value was less than 0.05.

**Results**

**In-vitro anti-AChE and anti-BChE activity of different extracts of P. armeniaca**

Anti-ChE activity of different extracts was evaluated comparing with rivastigmine as the reference drug (Table 1). Also, ChEI activity

| Samples | AChE IC₅₀ (µg/mL) | BChE IC₅₀ (µg/mL) |
|---------|------------------|------------------|
| ASI     | 356.75 ± 0.171   | > 500            |
| HSI     | 418.79 ± 0.365   | > 500            |
| SO      | 481.42 ± 0.447   | > 500            |
| ES      | 445.65 ± 8.42    | > 500            |
| ES₁     | > 500            | > 500            |
| AB₁     | 134.93 ± 2.88    | > 500            |
| HB₁     | > 500            | > 500            |
| BO      | > 500            | > 500            |
| EB      | > 500            | > 500            |
| EB₁     | > 500            | > 500            |
| Amygdalin | > 500        | > 500            |
| Rivastigmine | 2.77 ± 0.09   | 1.93 ± 0.03     |

*Data are expressed as Mean ± SE (three independent experiments).
of amygdalin as one of the main constituents was investigated to demonstrate whether it is responsible for the corresponding inhibitory activity (33, 34) (Table 1).

As shown in Table 1, AB1 illustrated the best anti-AChE activity with IC$_{50}$ = 134.93 μg/mL whereas HB1, BO, EB1 and EB counterparts depicted no AChEI activity. Our results revealed that AS1 showed moderate inhibitory activity against AChE (IC$_{50}$ = 356.75 μg/mL) and the corresponding HS1, SO, and ES extracts showed low activity with IC$_{50}$s = 418.79, 481.42, and 445.65 μg/mL, respectively. It was found that ES1 and amygdaline showed no inhibitory activity against AChE and probably is not responsible for anti-AChE activity of apricot kernels.

It should be noted that all extracts as well as amygdalin showed no anti-BChE activity.

**Neuroprotectivity against H$_2$O$_2$-induced cell death in PC12 neurons**

Aqueous extracts of AB1 and AS1 were selected for the investigation of *in-vitro* neuroprotective studies caused by H$_2$O$_2$ in differentiated PC12 neuron cells.

Also, similar assay was conducted for amygdalin whether the neuroprotectivity was caused by amygdalin (Figure 1). As shown in Figure 1, the percentage of cell viabilities was measured at the concentrations of 1, 10, 100 μg/mL of those extracts in comparison to the H$_2$O$_2$-treated group as the control at the concentration of 3 μg/mL.

According to our results, PC12 cells pretreated with AB1 significantly protected neurons against H$_2$O$_2$ at 10 and 100 μg/mL (cell viability = 70.49 and 81.47% with *P*-value < 0.0001). However, it depicted moderate neuroprotectivity against cell death at 1 μg/mL (cell viability = 60.54% with *P*-value < 0.01). It was found that aqueous extract of AS1 indicated remarkable neuroprotectivity at 100 μg/mL (cell viability = 70.71% with *P*-value < 0.0001). It exhibited no significant productivity at 1 and 10 μg/mL.

### Table 2. Total phenols and flavonoids content from aqueous extracts of *P. armeniaca*.

| Sample | Total phenols (µg GAE/mL) | Flavonoids (µg CE/mL) | Flavonoids/Phenolics |
|--------|---------------------------|-----------------------|----------------------|
| AS1    | 21.33±0.06                | 16.07±0.03            | 0.75                 |
| AB1    | 18.61±0.51                | 7.32±0.17             | 0.39                 |

**Figure 1.** Neuroprotective effect of AS1, AB1 and amygdalin on cell viability of PC12 cells in H$_2$O$_2$-induced damage. Data are expressed as mean SD and one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test was carried out to determine the level of significance. **P** < 0.01, ****P < 0.0001 vs. control. am: amygdalin; AS1: aqueous extract of sweet apricot kernels; AB1: aqueous extract of bitter apricot kernels.
Similar *in-vitro* evaluation of amygdalin at concentration of 1, 10, and 100 µg/mL showed no neuroprotectivity.

**Determination of total phenolic and flavonoid content**

Total phenolic and flavonoid content of aqueous extracts was reported in Table 2. As can be seen in Table 2, the extract of AS1 contained more total phenolic and flavonoids content than AB1 suggesting that AChEI activity is independent of phenolic and flavonoid compounds.

**Discussion**

AD is one of the most common types of dementia. In this respect, various synthetic and plant-derived ChEIs are usually used for the management and amelioration of the disease (15). In this study, *P. armeniaca* kernels were candidate to be examined for their anti-AD activities via ChEI and neuroprotective properties. The selection of kernels comes back to the efficacy of apricot kernels recommended for the prevention and treatment of memory loss in Iranian traditional medicine (ITM). For this purpose, a wide range of plants have been introduced in ITM which have been thoroughly investigated in the recent studies (27). Also, the presence of glycosides in the kernels may found to be suitable as they are one of the major classes of those compounds documented to possess ChEI activity (35, 36).

It seems that the plants belonging to Rosaceae family containing CNGs have depicted anti-ChE activity (37, 38). According to the literature available, the concentration of constituents and biological properties of apricot kernels not only are affected by the kinds of apricot kernels (sweet or bitter) and solvent extraction, but also are affected by the variety, geographic region, and collection time (34, 39, 40). Hence, anti-ChE and neuroprotective activities of aqueous, hydroalcoholic, petroleum ether, and ethanolic extracts of both sweet and bitter kernels of apricot cultivated in north-western Iran were investigated. In addition, similar studies were conducted for amygdalin as the main constituent of kernels whether it is responsible for the desired activities.

Our results revealed that aqueous extract of bitter apricot kernels showed potent *in-vitro* acetylcholinesterase inhibitory and neuroprotective effects. However, regarding to results reported in Table 1, amygdalin demonstrated no biological effects. Therefore, the observed effects probably are associated to the synergistic effects of several compounds. It is worth mentioning that AChEI activity of some plants from family Rosaceae including *Agrimonia eupatoria*, *Amygdalus scoparia*, *Coussapoa microcarpa*, *Cotoneaster nummularia*, *Rosa canina*, and *Rosa damascene* depicted low inhibitory activity and *P. armeniaca* was found much more potent than those reported in the literature (41).

Another instructive point relates to the study reported by Cheng et al., which revealed that amygdalin has improved nerve growth factor (NGF)-induced neuritogenesis and reduced 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in rat dopaminergic PC12 cells (24). On the other side, prunasin known as CNGs which is ubiquitous in the apricot kernels has shown neuroprotective activity in NG108-15 hybridoma cells (42). The neuroprotectivity of bitter kernels may be related to the presence of flavonoids since these compounds have been found as effective neuroprotective agents (43, 44). For example, it has been revealed that the consumption of green tea led to the reduction of risk of Parkinson’s disease (43, 45).

In a study reported by Tohda et al., a kampo formula composed of *P. armeniaca* L., which is used for the improvement of learning impairment and synaptic loss in the patients with AD, was studied for its neuroprotective abilities in mice (46). It was found that synergistic effects played an important role in directly activating neurons.

There are various reports confirming that cyclooxygenase2 (COX-2) overexpression causes alteration of neuronal cell cycle in a murine model of AD and COX-2 inhibitors inhibited the cell-cycle in the early phase of βAP toxicity (47). Also, in a study reported by Yang et al., amygdalin which was extracted from the seeds of *Prunus armeniaca* L. suppressed COX-2 and inducible nitric oxide synthase (iNOS) expressions in mouse BV2 microglial cells. It can be considered as an
auxiliary role for the cognitive enhancement (48). However, it seems that further investigations are required to determine the exact mechanism of action of apricot kernels as an anti-AD agent.

**Conclusion**

In conclusion, in-vitro ChE inhibitory and neuroprotective activities of various extractions of bitter and sweet apricot kernels (*P. armeniaca* L.) were investigated. Our results demonstrated that the best anti-AChE activity and neuroprotectivity against *H*₂*O*₂-induced cell death in PC12 neurons were obtained by the aqueous extract of bitter type. To gain insight into more effective constituent responsible for the desired biological activities, amygdalin as the most abundant compound in the apricot kernels was similarly evaluated. As amygdalin showed neither ChE inhibitory nor neuroprotective activities the synergistic effects of multiple compounds are probably involved in inducing desired biological activities. Also, it is suggested that inhibitory activity of kernels extracts should be evaluated against different factors involved in the creation of AD such as βA aggregation, phosphorylation of tau proteins, and beta secretase (BACE1) to find the possible mechanism of action of apricot kernels for the treatment of dementia and improvement of memory to develop plant-mediated neurodegenerative drug discovery.

**Acknowledgements**

The authors thank Dr. Mahdieh Eftekhari and staff of Laboratory of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences. This research was part of a M.Sc thesis which was supported by a grant from the Research Council of Tabriz University of Medical Sciences [grant number 5-71-1820]. The study protocol was approved by the Ethics Committee of Tabriz University Medical sciences (TBZMED.REC.1394.1049)

**References**

1. Alzheimer’s A. 2015 Alzheimer’s disease facts and figures. *Alzheimers Dement.* (2015) 11: 332-84
2. Amaducci LA, Rocca WA and Schoenberg BS. Origin of the distinction between Alzheimer’s disease and senile dementia How history can clarify nosology. *Neurology* (1986) 36: 1497-9.
3. Prince M, Comas-Herrera A, Knapp M, Guerchet M and Karagiannidou M. World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future. London, UK: Alzheimer’s Disease International (2016).
4. Muñoz-Torrello D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer’s disease. *Curr. Med. Chem.* (2008) 15: 2433-55.
5. LaFerla FM, Green KN, and Oddo S. Intracellular amyloid-β in Alzheimer’s disease. *Nat. Rev. Neurosci.* (2007) 8: 499-509.
6. Ballatore C, Lee VM-Y and Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. *Nat. Rev. Neurosci.* (2007) 8: 663-72.
7. Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C and Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. *Redox. Biol.* (2018) 14: 450-64.
8. Darvesh S, Hopkins DA and Geula C. Neurobiology of butyrylcholinesterase. *Nat. Rev. Neurosci.* (2003) 4: 131-8.
9. Mueller C, Perera G, Hayes RD, Shetty H and Stewart R. Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer’s disease: a retrospective survival analysis. *Age Ageing* (2017) 47: 88-94.
10. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, Yu Q-S, Mameczarz J, Holloway HW and Giordano T. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. *Proc. Natl. Acad. Sci. U.S.A.* (2005) 102: 17213-8.
11. Small DH, Moir RD, Fuller SJ, Michaelson S, Bush AI, Li QX, Milward E, Hilbich C and Weidemann A. A protease activity associated with acetylcholinesterase releases the membrane-bound form of the amyloid protein precursor of Alzheimer’s disease. *Biochemistry* (1991) 30: 10795-9.
12. Guillozet A, Mesulam MM, Smiley J and Mash D. Butyrylcholinesterase in the life cycle of amyloid plaques. *Ann. Neurol.* (1997) 42: 909-18.
13. Li Y, Hai S, Zhou Y, and Dong BR. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. *Syst. Rev.* (2015) Cd009444.
14. Šešok S, Bolle N, Kobal J, Bucík V and B V odušek D. Cognitive function in early clinical phase huntington disease after rivastigmine treatment. *Psychiatr. Danub.* (2014) 26: 239-48.
15. Wszelaki N, Kuciun A and Kiss A. Screening
of traditional European herbal medicines for acetylcholinesterase and butyrylcholinesterase inhibitory activity. Acta Pharm. (2010) 60: 119-28.

(16) Adams M, Gmünder F and Hamburger M. Plants traditionally used in age related brain disorders—A survey of ethnomedical plant literature. J. Ethnopharmacol. (2007) 113: 363-81.

(17) Akram M and Nawaz A. Effects of medicinal plants on Alzheimer’s disease and memory deficits. Neural Regen. Res. (2017) 12: 660-70.

(18) Su Y, Wang Q, Wang C, Chan K, Sun Y and Kuang H. The treatment of Alzheimer’s disease using Chinese medicinal plants: from disease models to potential clinical applications. J. Ethnopharmacol. (2014) 152: 403-23.

(19) Kurt BZ, Gazioglu I, Seygi E and Sönnmez F. Anticholinesterase, Antioxidant, Antiinflammatogenic Activities of Ten Edible Wild Plants from Ordu Area, Turkey. Iran J. Pharm. Res. (2018) 17: 1047-56.

(20) Raj V, Jain A and Chaudhary J. Prunus armeniaca (Apricot): an overview. J. Pharm. Res. (2012) 5: 3964-6.

(21) Rai I, Bachheti R, Saini C, Joshi A and Satyan R. A review on phytochemical, biological screening and importance of Wild Apricot (Prunus armeniaca L.). Orient. Pharm. Exp. Med. (2016) 16: 1-15.

(22) Karasvuran N, Charehsaz M, Celik H, Asma BM, yakinci C and Aydin A. Amygdalin in bitter and sweet seeds of apricots. Environ. Toxicol. Chem. (2014) 96: 1564-70.

(23) Katayama S, Ogawa H and Nakamura S. Apricot carotenoids possess potent anti-amyloidogenic activity in-vitro. J. Agric. Food Chem. (2011) 59: 12691-6.

(24) Cheng Y, Yang C, Zhao J, Tse HF and Rong J. Proteomic identification of calcium-binding chaperone calreticulin as a potential mediator for the neuroprotective and neuritogenic activities of fruit-derived glycoside amygdalin. J. Nutr. Biochem. (2015) 26: 146-54.

(25) Yang C, Zhao J, Cheng Y, Li X and Rong J. Bioactivity-guided fractionation identifies amygdalin as a potent neurotrophic agent from herbal medicine Semen Persicae extract. Biomed. Res. Int. (2014) 2014: 306857.

(26) Jorjani SI. Yadegar on Medicine and Pharmacology (Mohaghegh, M., ed.). Tehran: Iran: Institute of Islamic Studies in Tehran. (2003) 44: 31.

(27) Saeedi M, Babaie K, Karimpour-Razkenari E, Vazirian M, Akbarzadeh T, Khanavi M, Hajimahmoodi M and Shams Ardekan MR. In-vitro cholinesterase inhibitory activity of some plants used in Iranian traditional medicine. Nat. Prod. Res. (2017) 31: 2690-4.

(28) Saeedi M, Vahedi-Mazdabadi Y, Rastegari A, Soleimani M, Eftekhari M, Akbarzadeh T, Khanavi M. Evaluation of Asarum europaeum L. Rhizome for the Biological Activities Related to Alzheimer’s Disease. Res. J. Pharmacogn. (2020) 7: 25-33.

(29) Saeedi M, Safavi M, Karimpour-Razkenari E, Mahdavi M, Efradi N, Moghadam FH, Khanavi M and Akbarzadeh T. Synthesis of novel chromenes linked to 1, 2, 3-triazole ring system: Investigation of biological activities against Alzheimer’s disease. Bioorg. Chem. (2017) 70: 86-93.

(30) Gerlier D and Thomasset N. Use of MTT colorimetric assay to measure cell activation. J. Immunol. Methods. (1986) 94: 57-63.

(31) Singleton VL, Orthofer R and Lamuela-Raventós RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of folinicic acid reagent. Meth. Enzymol. (1999) 299: 152-78.

(32) Marinova D, Ribarova F and Atanassova M. Total phenolics and total flavonoids in Bulgarian fruits and vegetables. J. Univ. Chem. Technol. Metallurgy (2005) 40: 255-60.

(33) Savic IM, Nikolic VB, Savic-Gajic IM, Nikolic LB, Ibric SR and Gajic DG. Optimization of technological procedure for amygdalin isolation from plum seeds (Pruni domesticae semen). Front. Plant Sci. (2015) 6: 276.

(34) Lv W-F, Ding M-Y and Zheng R. Isolation and quantitation of amygdalin in Apricot-kernel and Prunus Tomentosa Thunb. by HPLC with solid-phase extraction. J. Chromatogr. Sci. (2005) 43: 383-7.

(35) Suchaichit N, Kanokmedhakul S, Kanokmedhakul K, Mooosophon P, Boonyarat C, Plekratoke K, Tearavarich R and Suchaichit NP. Phytochemical investigation and acetylcholinesterase inhibitory activity of bark of Hymenodictyon orixense. Nat. Prod. Res. (2018) 32: 2936-9.

(36) Nugroho A, Choi JS, Hong J-P and Park H-J. Anti-acetylcholinesterase activity of the aglycones of phenolic glycosides isolated from Leonurus japonicus. Acta Pharm. (2015) 6: 276.

(37) Mukherjee PK, Kumar V, Mal M and Houghton PJ. Acetylcholinesterase inhibitors from plants. Phytomedicine (2007) 14: 289-300.

(38) Murray AP, Faraoni MB, Castro MJ, Alza NP and Cavallaro V. Natural AChE inhibitors from plants and their contribution to Alzheimer’s disease therapy. Curr. Neuropharmacol. (2013) 11: 388-413.

(39) Yıldırım FA, Yıldırım AN, Şan B, Aşkın MA and Polat M. Variability of phenolics and mineral composition in kernels of several bitter and sweet
apricot (Prunus armeniaca Batsch.) cultivars. J. Food Agri. Environ. (2010) 8: 179-84.

(40) Stoewsand G, Anderson J and Lamb R. Cyanide content of apricot kernels. J. Food Sci. (1975) 40: 1107.

(41) Esmaeili S, Ara L, Hajimehdipoor H, Kolivand H and Mohammadi Motamed S. Acetylcholinesterase inhibitory effects of some plants from Rosaceae. Res. J. Pharmacogn. (2015) 2: 33-7.

(42) Tan HP, Wong DZH, Ling SK, Chua H and Kadir HA. Neuroprotective activity of galloylated cyanogenic glucosides and hydrolysable tannins isolated from leaves of Phyllagathis rotundifolia. Fitoterapia (2012) 83: 223-9.

(43) Vauzour D, Vafeiadou K, Rodriguez-Mateos A, Rendeiro C and Spencer JP. The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr. (2008) 3: 115-26.

(44) Dajas F, Rivera F, Blasina F, Arredondo F, Echeverry C, Lafon L, Morquio A and Heizen H. Cell culture protection and in-vivo neuroprotective capacity of flavonoids. Neurotox. Res. (2003) 5: 425-32.

(45) Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth Jr WT and Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol. (2002) 155: 732-8.

(46) Tohda C, Tamura T and Komatsu K. Repair of amyloid β (25–35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to. Brain Res. (2003) 990: 141-7.

(47) Xiang Z, Ho L, Valdellon J, Borchelt D, Kelley K, Spielman L, Aisen PS and Pasinetti GM. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer’s disease neuropathology. Neurobiol. Aging (2002) 23: 327-34.

(48) Yang H-Y, Chang H-K, Lee J-W, Kim Y-S, Kim H, Lee M-H, Shin M-S, Ham D-H, Park H-K and Lee H. Amygdalin suppresses lipopolysaccharide-induced expressions of cyclooxygenase-2 and inducible nitric oxide synthase in mouse BV2 microglial cells. Neurol. Res. (2007) 29: 59-64.

This article is available online at http://www.ijpr.ir